Cargando…
Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis
Dalfampridine extended release (ER) 10 mg is an oral tablet form of the potassium (K(+)) channel-blocking compounded dalfampridine, also known as fampridine, and chemically 4-aminopyridine or 4-AP, which received regulatory approval in the United States for the treatment of walking in patients with...
| Autor principal: | |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3090287/ https://www.ncbi.nlm.nih.gov/pubmed/21573085 http://dx.doi.org/10.2147/NDT.S10469 |